Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Statins Potentiate Aminopeptidase Inhibitor (pro)Drug Activity in Acute Myeloid Leukemia Cells

Jacqueline Cloos, PhD, Godefridus J Peters, PhD, Marjon Al, BSc, Yehuda G Assaraf, PhD, Lixia Wang, PhD, Jack W. Singer, MD, Jorge E. Cortes, MD, Gert J. Ossenkoppele, MD PhD, Gerrit Jansen, PhD

Blood (2018) 132 (Supplement 1): 3945.

https://doi.org/10.1182/blood-2018-99-114447

Published: 2018

Journal Articles

Results of a Phase 3 Randomised Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma Not Eligible for Stem Cell Transplantation

Gilles Andre Salles, Wojciech Jurczak, David J. Andorsky, MD, Donald P. Quick, MD, Jack W. Singer, MD, Simran Bedi Singh, Lixia Wang, PhD, Anton Egorov, MD, Christine Gabarroca, MSc, Ruth Pettengell, MD

Blood (2018) 132 (Supplement 1): 4189.

https://doi.org/10.1182/blood-2018-99-112455

Published: 2018

Journal Articles

Phase II Clinical Study of the Clinical Efficacy and Safety of Tosedostat in Patients with Myelodysplastic Syndromes (MDS) after Failure of Hypomethylating Agent-Based Therapy

Sangmin Lee, MD, Pinkal Desai, MDMPH, Bianca Edirisinghe, Samantha Pianello, Jack W. Singer, MD, Michael Samuel, MD, Ellen K Ritchie, MD, Gail J. Roboz, MD

Blood (2017) 130 (Supplement 1): 2966.

https://doi.org/10.1182/blood.V130.Suppl_1.2966.2966

Published: 2017

Journal Articles

LACK of IRON Binding by Pixantrone IS ASSOCIATED with Reduced PRODUCTION of Reactive Oxygen SPECIES and Myoctye Cytotoxicity IN VITRO.

Miles Hacker, Ph.D., Marc McKennon, Ph.D., Jack W. Singer, MD

Blood (2009) 114 (22): 4806.

https://doi.org/10.1182/blood.V114.22.4806.4806

Published: 2009

Journal Articles

Phase III Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin's Lymphoma (EXTEND): Results From the Treatment and Follow-up Periods.

Ruth Pettengell, MD, Bertrand Coiffier, MD, Geetha Narayanan, MD, Fernando Hurtado de Mendoza, MD, Raghunadharao Digumarti, MD, Henry Gomez, MD, Pier Luigi Zinzani, MD, Gary J Schiller, MD, David A Rizzieri, MD, Paul Cernohous, Lixia Wang, Jack W. Singer, MD

Blood (2009) 114 (22): 1677.

https://doi.org/10.1182/blood.V114.22.1677.1677

Published: 2009

Journal Articles

Selective Inhibition of Lysophosphatidic Acid Acyltransferase-β by CT32228 Inhibits MAPK and Enhances the Antileukemic Activity of Imatinib in BCR-ABL Expressing Cell Lines Resistant to Imatinib.

Paul La Rosée, MD, Taiping Jia, BS, Shadmehr Demehri, Peter de Vries, PhD, Lynn Bonham, PhD, Junia V. Melo, MD, PhD, Jack W. Singer, MD, PhD, Brian J. Druker, MD, Michael W. Deininger, MD, PhD

Blood (2005) 106 (11): 1524.

https://doi.org/10.1182/blood.V106.11.1524.1524

Published: 2005

Journal Articles

Molecular Characterization of PS-341 (bortezomib) Resistance: Implications for Overcoming Resistance Using Lysophosphatidic Acid Acyltransferase (LPAAT)-β Inhibitors.

Teru Hideshima, MD, PhD, Dharminder Chauhan, PhD, Kenji Ishitsuka, MD, PhD, Noopur Raje, MD, Shaji Kumar, MD, Klaus Podar, MD, PhD, Constantine Mitsiades, MD, PhD, Hiromasa Hideshima, Lynn Bonham, PhD, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Jack W. Singer, MD, Kenneth C. Anderson, MD

Blood (2004) 104 (11): 2411.

https://doi.org/10.1182/blood.V104.11.2411.2411

Published: 2004

NARROW

Statins Potentiate Aminopeptidase Inhibitor (pro)Drug Activity in Acute Myeloid Leukemia Cells

Results of a Phase 3 Randomised Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma Not Eligible for Stem Cell Transplantation

Phase II Clinical Study of the Clinical Efficacy and Safety of Tosedostat in Patients with Myelodysplastic Syndromes (MDS) after Failure of Hypomethylating Agent-Based Therapy

LACK of IRON Binding by Pixantrone IS ASSOCIATED with Reduced PRODUCTION of Reactive Oxygen SPECIES and Myoctye Cytotoxicity IN VITRO.

Phase III Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin's Lymphoma (EXTEND): Results From the Treatment and Follow-up Periods.

Selective Inhibition of Lysophosphatidic Acid Acyltransferase-β by CT32228 Inhibits MAPK and Enhances the Antileukemic Activity of Imatinib in BCR-ABL Expressing Cell Lines Resistant to Imatinib.

Molecular Characterization of PS-341 (bortezomib) Resistance: Implications for Overcoming Resistance Using Lysophosphatidic Acid Acyltransferase (LPAAT)-β Inhibitors.

Email alerts

ASH Publications

American Society of Hematology

Statins Potentiate Aminopeptidase Inhibitor (pro)Drug Activity in Acute Myeloid Leukemia Cells

Results of a Phase 3 Randomised Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma Not Eligible for Stem Cell Transplantation

Phase II Clinical Study of the Clinical Efficacy and Safety of Tosedostat in Patients with Myelodysplastic Syndromes (MDS) after Failure of Hypomethylating Agent-Based Therapy

LACK of IRON Binding by Pixantrone IS ASSOCIATED with Reduced PRODUCTION of Reactive Oxygen SPECIES and Myoctye Cytotoxicity IN VITRO.

Phase III Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin's Lymphoma (EXTEND): Results From the Treatment and Follow-up Periods.

Selective Inhibition of Lysophosphatidic Acid Acyltransferase-β by CT32228 Inhibits MAPK and Enhances the Antileukemic Activity of Imatinib in BCR-ABL Expressing Cell Lines Resistant to Imatinib.

Molecular Characterization of PS-341 (bortezomib) Resistance: Implications for Overcoming Resistance Using Lysophosphatidic Acid Acyltransferase (LPAAT)-β Inhibitors.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only